Galor Anat, Yoo Sonia H
Ophthalmic Surg Lasers Imaging. 2010 Mar 9:1-3. doi: 10.3928/15428877-20100215-07.
A 75-year-old man presented with an idiopathic central corneal perforation and was treated with cyanoacrylate glue and a bandage contact lens. The stromal bed healed but the patient was left with 360 degrees of corneal neovascularization. Bevacizumab eye drops (25 mg/mL) were prescribed for 1 month which caused marked regression of the blood vessels. A penetrating keratoplasty was performed and the patient continued to use the bevacizumab eye drops for 6 weeks after surgery. The patient noted decreased visual acuity 5 weeks after surgery and was found to have a melt in the stroma of the donor graft necessitating repeating therapeutic penetrating keratoplasty and Gunderson flap. This case highlights that whereas topical bevacizumab may aid in regression of acute corneal neovascularization, caution should be employed with its use in patients with a history of corneal melt.
一名75岁男性因特发性中央角膜穿孔就诊，接受了氰基丙烯酸酯胶水和绷带式隐形眼镜治疗。基质床愈合，但患者角膜出现360度新生血管。给予贝伐单抗滴眼液（25mg/mL）使用1个月，血管明显消退。进行了穿透性角膜移植术，术后患者继续使用贝伐单抗滴眼液6周。患者术后5周视力下降，发现供体移植物基质溶解，需要再次进行治疗性穿透性角膜移植术和冈德森皮瓣手术。该病例强调，虽然局部使用贝伐单抗可能有助于急性角膜新生血管消退，但有角膜溶解病史的患者使用时应谨慎。
